Chaitan S. Khosla's most recent trade in Entero Therapeutics Inc. was a trade of 24,889 Common Stock done . Disclosure was reported to the exchange on June 11, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Entero Therapeutics Inc | Chaitan S. Khosla | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 24,889 | 24,889 (0%) | 0% | 0 | Common Stock | |
| First Wave BioPharma Inc | Chaitan S. Khosla | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 52,980 | 52,980 | - | - | Stock Option (right to buy) | |
| First Wave BioPharma Inc | Chaitan S. Khosla | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 440 | 440 (0%) | 0% | - | Common Stock, par value $0.0001 per share | |
| First Wave BioPharma Inc | Chaitan S. Khosla | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 140 | 140 | - | - | Series G Non-Voting Convertible Preferred Stock |